|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Entire Cohort(n=12162) | Beta 3 Agonist(n=4329) | Anticholinergic(n=7833) | *p* |
| Age, *years* | 68 (+0.53) | 69 (+0.58) | 67 (+0.51) | <0.001 |
| RaceWhiteBlack/African AmericanAsianNone of the above | 5724 (47.0%)4105 (33.8%)183 (1.5%)2150 (17.7%) | 2816 (65.1%)688 (15.9%)67 (1.5%)758 (17.5%) | 2908 (37.1%)3417 (43.6%)116 (1.5%)1392 (17.8%) | <0.001 |
| EthnicityHispanic Not Hispanic None of the above | 742 (6.1%)9388 (77.2%)2032 (16.7%) | 237 (5.4%)3468 (80.1%)624 (14.5%) | 505 (6.4%)5920 (75.6%)1408 (18.0%) | <0.001 |
| InsuranceMedicaid/MedicarePrivateSelf-pay | 7346 (60.4%)4773 (39.2%)43 (0.4%) | 2766 (63.9%)1547 (35.7%)16 (0.4%) | 4580 (58.5%)3226 (41.2%)27 (0.3%) | <0.001 |
| Clinician SpecialtyUrogynecologyUrologyObstetrics/GynecologyPrimary Care | 2647 (21.8%)2586 (21.2%)2944 (24.2%)3985 (32.8%) | 1463 (33.8%)995 (23.0%)910 (21.0%)961 (22.2%) | 1184 (15.1%)1591 (20.3%)2034 (26.0%)3024 (38.6%) | <0.001 |